Summary:
While lipid nanoparticles are the most clinically advanced drug delivery system for nucleic acid therapeutics, they are only one tool in a toolbox of potential delivery vehicles. In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss additional tools, including polymeric nanoparticles, protein-based nanoparticles and extracellular vesicles with a focus on:
- Where LNPs potentially fall short
- Where different tools can enable therapeutic delivery
- Challenges to achieving meaningful clinical impact for these different vehicles
- Building out a portfolio of delivery vehicles
To learn more about the PODD Conference, please visit Drug-Delivery.org.
Moderators
Sanyogitta Puri, PhD
Sr Director, RNA & Gene Therapies - Non-Viral Delivery
Novo Nordisk
Panelists
Kanika Suri, PhD
Scientist, Drug Product Development, CMC
Takeda Pharmaceuticals
Anand Subramony, PhD
Vice President, Drug Delivery, Device, Connected Solutions & Innovation
Eli Lilly and Company
Vinu Krishnan, PhD
Principal Research Scientist, CMC Formulation Development & Drug Delivery
AbbVie
Ruchi Shah, PhD
Head US Drug Product, Vaccines Technical R&D
GSK
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.